ASPG and acute lymphoblastic leukemia: However, for children with ALL in the intermediate-high risk group, the EFS of children with AAP with interrupted asparaginase therapy was significantly lower than that of children who were re-exposed, with a 5.96-fold increased risk of tumour relapse or death.